Table 5.

Characteristics of patients included in the study

Subject ID	Gender	Race	Age (years)	Anti-EGFR Pretreatment	Response Assessment Method	ECOG PS	Best Response	EGFR Mutation Status	KRAS Mutation Status	Comments
CA-01-0006	Female	Black	75	Yes	RECIST	1	SD	Not done	KRAS −ve	15 weeks on trial with mixed tumor response, 8% decrease target lesions
CA-01-0015	Female	White	83	Yes	RECIST	0	SD	EGFR −ve	KRAS −ve	45 weeks on trial, cavitation of lesions on PET scan, 3% decrease target lesions
CA-01-0017	Female	White	60	Yes	RECIST	0	PD	EGFR −ve	KRAS +ve
CA-01-0063	Male	White	34	Yes	RECIST	1	PD	EGFR −ve	KRAS +ve
CA-01-0068	Female	Asian	49	Yes	RECIST	1	PD	EGFR −ve	Not done
CA-01-0069	Male	White	71	Yes	irRC	1	PD	EGFR −ve	KRAS +ve
CA-01-0070	Male	Hispanic	54	Yes	irRC	2	PD	EGFR +ve	KRAS −ve
CA-01-0072	Female	White	76	Yes	irRC	1	PD	Not done	Not done
CA-01-0074	Female	Hispanic	50	Yes	irRC	1	SD	EGFR −ve	KRAS +ve	16 weeks SD
CA-01-0075	Female	Asian	37	Yes	irRC	0	PD	EGFR −ve	KRAS −ve
CA-01-0056	Female	White	52	No	RECIST	0	SD	EGFR −ve	KRAS +ve	12 weeks,6% decrease target lesions after 2 doses/6 weeks
CA-01-0066	Female	White	70	No	RECIST	1	PD	EGFR −ve	Not done
CA-01-0073	Male	White	63	No	irRC	0	PD	EGFR −ve	KRAS +ve
CA-01-0076	Male	White	57	No	irRC	1	SD	EGFR −ve	KRAS −ve	18 weeks SD, 8.6% decrease target lesions
CA-01-0077	Female	White	64	No	irRC	0	PD	EGFR −ve	Not done
CA-01-0079	Male	White	53	No	irRC	1	PD	EGFR −ve	KRAS +ve